🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06446778
Recruiting Observational

Pipeline Embolization for Intracranial Aneurysms

NCT06446778 · tracked via the Priya Life Science China tracker
Sponsor
Zhujiang Hospital
Phase
Observational
Started
2022-09-01
Last updated
2024-11-18

Condition(s) studied

Efficacy, SelfHemodynamic InstabilityStenosisAneurysm, Intracranial

Investigational drug(s) / intervention(s)

Pipeline embolization device with or without shield technique

Pipeline embolization device with or without shield technique: The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.

Study summary

This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.

Eligibility

Sex
ALL
Min age
22 Years
Max age
75 Years
Healthy volunteers
No
Inclusion criteria: 1. Aged 22 to 75 years old, male or non-pregnant female; 2. UIA was diagnosed by CTA, MRA, or DSA; 3. The size of aneurysms is between 3 to 25mm; 4. Understands the nature of the procedure and provision of written informed consent; 5. Indications for FD implantation with or without adjunctive coiling; 6. Is willing to return to the investigational site for follow-up according to our protocol. Exclusion criteria: 1. With contraindications to flow-diversion treatment or known allergy to cobalt-chromium alloy or contrast medium; 2. Pregnancy or lactation; 3. Coexist with other vascular lesions (coronary artery disease, abdominal aortic aneurysm, severe intracranial artery stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.); 4. Parent vessel with a diameter \<2.0 mm or ≥5.0 mm.; 5. Unwilling to be followed up or likely to have poor treatment compliance; 6. Life expectancy less than 3 years; 7. Inability to receive anti-platelet or anticoagulant medication; 8. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4); 9. Enrollment in another trial or other situations that the researcher deems unsuitable for inclusion in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhujiang hospital Guangzhou Guangdong Recruiting

More Zhujiang Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06446778 on ClinicalTrials.gov ↗ ← All trials in China